In a regulatory filing, Krystal Biotech director Dino Rossi disclosed the sale of 40,000 common shares of the company on March 1 at a price of $83.2493 per share.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KRYS:
- Krystal Biotech upgraded to Buy from Neutral at Goldman Sachs
- Krystal Biotech reports Q4 EPS ($1.25), consensus ($1.32)
- Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
- Krystal Biotech CEO sells $4.04M in common stock
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis